| 1. |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
|
| 2. |
Foxtrot Collaborative Group None. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol, 2012, 13(11): 1152-1160.
|
| 3. |
Karoui M, Rullier A, Piessen G, et al. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage Ⅱ and Ⅲ colon cancers: a phase Ⅱ multicenter randomized controlled trial (PRODIGE 22). Ann Surg, 2020, 271(4): 637-645.
|
| 4. |
Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.
|
| 5. |
Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology, 2005, 47(2): 141-146.
|
| 6. |
Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase Ⅱ trial. Acta Oncol, 2015, 54(10): 1747-1753.
|
| 7. |
Liu F, Yang L, Wu Y, et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial. Chin J Cancer Res, 2016, 28(6): 589-597.
|
| 8. |
Zhou H, Song Y, Jiang J, et al. A pilot phase Ⅱ study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res, 2016, 28(6): 598-605.
|
| 9. |
Arredondo J, Baixauli J, Pastor C, et al. Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery. Clin Transl Oncol, 2017, 19(3): 379-385.
|
| 10. |
Dehal A, Graff-Baker AN, Vuong B, et al. Neoadjuvant chemotherapy improves survival in patients with clinical T4b colon cancer. J Gastrointest Surg, 2018, 22(2): 242-249.
|
| 11. |
Seymour MT, Morton D, International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1 052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol, 2019, 37(15 suppl): 3504.
|
| 12. |
de Gooyer JM, Verstegen MG, ’t Lam-Boer J, et al. Neoadjuvant chemotherapy for locally advanced T4 colon cancer: a nationwide propensity-score matched cohort analysis. Dig Surg, 2020, 37(4): 292-301.
|
| 13. |
Rosander E, Nordenvall C, Sjövall A, et al. Management and outcome after multivisceral resections in patients with locally advanced primary colon cancer. Dis Colon Rectum, 2018, 61(4): 454-460.
|
| 14. |
Lehnert T, Methner M, Pollok A, et al. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg, 2002, 235(2): 217-225.
|
| 15. |
Wasmann KATGM, Klaver CEL, van der Bilt JDW, et al. Subclassification of multivisceral resections for T4b colon cancer with relevance for postoperative complications and oncological risks. J Gastrointest Surg, 2020, 24(9): 2113-2120.
|
| 16. |
Govindarajan A, Coburn NG, Kiss A, et al. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst, 2006, 98(20): 1474-1481.
|
| 17. |
Yang X, Zhong ME, Xiao Y, et al. Laparoscopic vs open resection of pT4 colon cancer: a propensity score analysis of 94 patients. Colorectal Dis, 2018, 20(11): O316-O325.
|
1/5
WeChat